ClinicalTrials.gg
CompletedNCT04336449Updated Aug 14, 2020

Eptinezumab in Healthy Japanese Subjects

A Phase 1 interventional study of Eptinezumab and Placebo in Healthy, sponsored by H. Lundbeck A/S. Completed at 1 site in Japan. Open to participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-14.

Sponsored by H. Lundbeck A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
20 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to investigate how eptinezumab enters, moves through and exits the body. Safety and tolerability will also be investigated.

Read the detailed description

The study will consist of 18 healthy Japanese subjects, divided into two single dose cohorts with 9 subjects in each cohort.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Healthy Japanese subjects with a of ≥ 18.5 and ≤ 25 kg/m2

Other in- and exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Cohort 1 100 mg eptinezumab

    Drug: Eptinezumab

  • Experimental
    Cohort 2 300 mg eptinezumab

    Drug: Eptinezumab

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Eptinezumab - single intravenous infusion

  • DrugPlacebo

    Placebo - single intravenous infusion

06

What researchers measure

Primary outcomes

  1. Cmax eptinezumab

    maximal observed plasma concentration

    Time frame: From dosing to week 12

  2. AUC(0-t) eptinezumab

    area under the plasma concentration-time curve from zero to time t

    Time frame: From dosing to week 12

  3. AUC(0-inf) eptinezumab

    area under the plasma concentration-time curve from zero to infinity

    Time frame: From dosing to week 12

  4. Systemic Clearance of eptinezumab

    Time frame: From dosing to week 12

07

Study locations

1 site
  • P-One Clinic
    Tokyo, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2020 to primary completion in Aug 2020, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2020
First posted
Apr 7, 2020
StartActual
Apr 1, 2020
Primary completionActual
Aug 13, 2020
CompletionActual
Aug 13, 2020
Last update
Aug 14, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04336449
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Apr 7, 2020
Start date
Apr 1, 2020
Primary completion
Aug 13, 2020
Completion
Aug 13, 2020
Last update
Aug 14, 2020

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@Lundbeck.com

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eptinezumab

Start the discussion